Following President Donald Trump’s recent signing of the Food and Drug Administration (FDA) Reauthorization Act, Biotechnology Innovation Organization (BIO) officials released a statement of support celebrating the legislation reauthorizing prescription drug user fees.
“President Trump’s signature today on this landmark legislation is the culmination of a years-long collaborative process in which patients, industry, FDA, legislators and other stakeholders worked tirelessly to identify ways in which FDA’s human drug review programs can be improved to deliver better health care for every American and enhance the incorporation of the patient voice in drug development and review,” BIO president and CEO James Greenwood said.
The association’s leader expressed pride in BIO’s role leading up to the measure’s enactment, adding that the organization is “prouder still” of what resulting medical innovations will mean for patients going forward.
“We look forward to working … to ensure that these critical advancements are most effectively implemented,” Greenwood said. “We thank the leaders from both parties and in both chambers of Congress for their tireless bipartisan efforts in crafting this historic achievement.”
Based in Washington, D.C., BIO is the world’s largest biotech trade association, convening an annual meeting in the U.S. as well as regional meetings overseas. Its members comprise representatives from the pharmaceutical, biofuel and agriculture industries.